Levetiracetam
(Synonyms: 左乙拉西坦; UCB L059) 目录号 : GC17779
An antiepileptic compound
Cas No.:102767-28-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Levetiracetam (LEV) is a newly developed antiepileptic drug (AED) with a broad spectrum of efficacy against partial and generalized seizures. [1]
The mode of action of LEV seems to be different from other AED. Synaptic vesicle protein 2A which can block calcium release from intraneuronal stores is shown to be the binding site of levetiracetam. Thus, it works against the negative modulators of gamma-aminobutyric acid and glycin-gated currents. Moreover, LEV does not have the ablility to induce cytochrome P450 isoenzyme.[2]
A study has shown that an oral dose of LEV can’t bind to plasma proteins, while no hepatic metabolism was observed. One-third of the metabolized drug was found to be hydrolyzed and the others were excreted unchanged in the urine.[3]
References:
[1] Nabil J. Azar, Patsy Aune. Acute pancreatitis and elevated liver transaminases after rapid titration of oral levetiracetam. Journal of Clinical Neuroscience. June 2014. 21(6): 1053-1054.
[2] Xiao-Qiao Chen, Wei-Na Zhang, Zhi-Xian Yang, Meng Zhao, Fang-Cheng Cai, Shao-Ping Huang, Li Gao, Bao-Dong Pang, Xi Chen, Li-Ping Zou. Efficacy of Levetiracetam in Electrical Status Epilepticus During Sleep of Children: A Multicenter Experience. Pediatric Neurology. March 2014. 50(3): 243-249.
[3] Shahnaz Akhtar Chaudhry, Geert’t Jong, Gideon Koren. The fetal safety of Levetiracetam: A systematic review. Reproductive Toxicology. July 2014. 46: 40-45.
| Cas No. | 102767-28-2 | SDF | |
| 别名 | 左乙拉西坦; UCB L059 | ||
| 化学名 | (2S)-2-(2-oxopyrrolidin-1-yl)butanamide | ||
| Canonical SMILES | CCC(C(=O)N)N1CCCC1=O | ||
| 分子式 | C8H14N2O2 | 分子量 | 170.21 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 16.7 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.8751 mL | 29.3755 mL | 58.751 mL |
| 5 mM | 1.175 mL | 5.8751 mL | 11.7502 mL |
| 10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet